- ALL
- New Technologies and New Products——Efficacy and Evidence-Based Applications of Ergothioneine
- Infant and Toddler Formula Milk Powder and Complementary Food——Tracking Scientific Research Achievements and Ingredient Innovation
- Infant and Toddler Formula Milk Powder and Complementary Food——Precise Formulation and Clinical Evidence
Sessions
Section II:New Technologies and New Products——Session 2:Efficacy and Evidence-Based Applications of Ergothioneine |
2026-03-14 09:00-12:00 Dongyu,Hesheng room(Wanquan Ballroom 1/3) |
Moderator：He Tao,Deputy Director,Key Laboratory of Food Nutrition and Health Evaluation Technology,State Administration for Market Regulation |
| 2026-03-14 09:00-09:20 Synthetic Biology of Ergothioneine and Investigation into Its Anti-Aging Properties |
| 2026-03-14 09:20-09:40 Dr.Ergo® Ergothioneine:Re-establishing the Value of the 5th-Generation Smart Antioxidants Based on Clinical Evidence |
| 2026-03-14 09:40-10:00 Synergistic Inhibition of Acrolein Activity by Ergothioneine and GABA:In Vitro and In Vivo Studies |
| 2026-03-14 10:00-10:20 |
| 2026-03-14 10:20-10:40 The protective effect of ergothioneine on oxidative damage of nerve cells |
| 2026-03-14 10:40-11:00 Green Biomanufacturing,Efficacy and Applications of Ergothioneine |
| 2026-03-14 11:00-11:55 Roundtable Meeting：The Development Path of Ergothioneine in China |
| 2026-03-14 11:55-12:00 |
Section VIII:Infant and Toddler Formula Milk Powder and Complementary Food——Section 1:Tracking Scientific Research Achievements and Ingredient Innovation |
2026-03-13 13:30-15:50 Dongyu,Hesheng room(Wanquan Ballroom 1/3) |
| 2026-03-13 13:30-13:35 |
| 2026-03-13 13:35-13:50 Guiding Report： Precision Formulation Design and Biofabrication of Next-Generation Infant Formula |
| 2026-03-13 13:50-14:05 |
| 2026-03-13 14:05-14:20 Establishment,Standardization and Application of a National Human Milk and Maternal-Infant Nutrition Database in China |
| 2026-03-13 14:20-14:35 Deciphering the Structural Diversity and Synergism of Human Milk Oligosaccharides (HMOs):Latest Advances in Infant Nutrition Science and Clinical Research |
| 2026-03-13 14:35-14:50 Synbiotics:Regulation of Infant Gut Microbiota and Immune Development |
| 2026-03-13 14:50-15:05 Studies on the Short- and Long-Term Health Outcomes of Milk Fat Globule Membrane (MFGM) in Infants and Toddlers |
| 2026-03-13 15:05-15:20 Advances in Research and Application of Structured Lipids Mimicking Human Milk Fat |
| 2026-03-13 15:20-15:35 Digital Technology Empowers Precision Health Management for Infants |
| 2026-03-13 15:35-15:50 |
Section VIII:Infant and Toddler Formula Milk Powder and Complementary Food——Section 2:Precise Formulation and Clinical Evidence |
2026-03-13 15:50-17:35 Dongyu,Hesheng room(Wanquan Ballroom 1/3) |
| 2026-03-13 15:50-16:05 Based on Human Milk Research:Investigation of 3D Fat Globule-Mediated Effects on Infant Health |
| 2026-03-13 16:05-16:20 Infant Brain and Immune Maturation:Rational Design and Clinical Validation of Human Milk-Mimetic Infant Formulas |
| 2026-03-13 16:20-16:35 |
| 2026-03-13 16:35-16:50 A Randomized,Double-Blind,Placebo-Controlled Study Evaluating the Impact of OPO-Enriched Infant Formula on Fat and Calcium Bioavailability,and Infant Defecatory Characteristics |
| 2026-03-13 16:50-17:05 The Health-Promoting Effects of Lactoferrin During Early Life:A Real-World Study in Chinese Infants |
| 2026-03-13 17:05-17:20 Health-Promoting Effects and Clinical Evaluation of Next-Generation HMO-Enriched Formulas |
| 2026-03-13 17:20-17:35 Impact of Bifidobacterium infantis YLGB-1496 Isolated from Chinese Human Milk on the Health Status of Infants and Toddlers Aged 0–36 Months |